Abstract
Objectives
We analyzed the costs and outcomes of lung transplant in Portugal and its evolution since it was first performed in 2000.
Methods
Data were collected for all patients waiting for transplant from 31 December 2000 until 31 December 2010 (n = 61). Patients waiting for transplant were used as the comparison group. We calculated the mean restricted survival time using the Kaplan–Meier estimation method. The time horizon was closed upon the death of the last surviving patient. Costs and consequences were discounted at 5 % per annum. We calculated the incremental cost-effectiveness ratio of transplant as compared to no transplant. Deterministic and probabilistic sensitivity analyses were performed. We tested volume-outcome effects using a parametric survival regression.
Results
The cost of lung transplantation was 77,223€ per QALY and 121,276€ per life-year. Assuming a 50,000€/QALY willingness-to-pay, lung transplant would be cost-effective with a 37 % probability. Survival improved substantially from 5.15 years over the 2001–2010 period to 6.94 years for the 2008–2010 period. When restricting our analysis to the 2008–2010 period, the cost-effectiveness ratio decreased to €79,016 per life-year gained and €69,241 per QALY. Survival was significantly associated with the number of procedures performed.
Conclusion
Although above commonly accepted cost-effectiveness thresholds, the economic value of lung transplant holds promise in Portugal due to the large improvement in survival over the 2001–2010 period. The life-threatening character of the motivating conditions, the absence of alternative treatment, and equity concerns should be also accounted for when assessing the “value for money” of lung transplant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Christie, J.D., Edwards, L.B., Kucheryavaya, A.Y., Benden, C., Dipchand, A.I., Dobbels, F., Kirk, R., Rahmel, A.O., Stehlik, J., Hertz, M.I.: International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J. Heart Lung Transpl. 31(10), 1073–1086 (2012)
Halm, E.A., Lee, C., Chassin, M.R.: Is volume related to outcome in health care? A systematic review and methodological critique of the literature. Ann Int Med 137(6), 511–520 (2002)
Neymark, N., Adriaenssen, I., Gorlia, T., Caleo, S., Bolla, M.: Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 11(3), 233–248 (2002)
Anyanwu, A.C., McGuire, A., Rogers, C.A., Murday, A.J.: An economic evaluation of lung transplantation. J. Thorac. Cardiovasc. Surg. 123(3), 411–420 (2002)
Anyanwu, A.C., McGuire, A., Rogers, C.A., Murday, A.J.: Assessment of quality of life in lung transplantation using a simple generic tool. Thorax 56, 218–222 (2001)
Administração Central do Sistema de Saúde (ACSS, Central Administration of the Health System): Base de Dados dos Elementos Analíticos. Ministério da Saúde, Administração Central do Sistema de Saúde (2013). http://www.acss.min-saude.pt/bdea/, last Accessed 3rd May 2013
Diário da República: Portaria 839-A/2009. Portugal (2009)
Infarmed [National Authority of Medicines and Health Products, IP]: Estatística do Medicamento 2008 [Drug Statistics 2008], Ministry of Health, Lisbon (2008)
Pordata. Base de Dados Portugal Contemporâneo [Database Contemporary Portugal]. http://www.pordata.pt/Portugal/Ambiente+de+Consulta/Tabela, last Accessed 3rd May 2013
Silva, E.A., Pinto, C.G., Sampaio, C., Pereira, J.A., Drummond, M., Trindade, R.: Orientações metodológicas para estudos de avaliação económica de medicamentos. Infarmed, Ministry of Health, Lisbon (1998)
Andronis, L., Barton, P., Bryan, S.: Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Prepress Projects (2009)
Latimer, N.: NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation With Patient-Level Data. Report by the Decision Support Unit. School of Health and Related Research. University of Sheffield, UK (2013)
Organization for Economic Cooperation and Development. OECD.StatExtracts. http://stats.oecd.org/Index.aspx?DataSetCode=CPL, last seen on 5th April 2013
XE Currency converter, http://www.xe.com/currencyconverter/, last seen on 5th April 2013
Groen, H., van der Bij, W., Koeter, G.H., Tenverget, E.M.: Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease. Am. J. Transpl. 4, 1155–1162 (2004)
Vasiliadis, H.M., Collet, J.P., Penrod, J.R., Ferraro, P., Poirier, C.A.: Cost-effectiveness and cost-utility study of lung transplantation. J. Heart Lung Transpl. 24(9), 1275–1283 (2005)
NICE guide to the methods of health technology appraisal. London: NICE (2013)
National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. January 2009. http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf, last Accessed 28th May (2013)
Glanville, A.R., Estenne, M.: Indications, patient selection and timing of referral for lung transplantation. Eur. Respir. J. 22(5), 845–852 (2003)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mendonça, L., Perelman, J., Rodrigues, V. et al. Cost-effectiveness of lung transplantation and its evolution: the Portuguese case. Eur J Health Econ 15, 767–772 (2014). https://doi.org/10.1007/s10198-013-0522-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-013-0522-z